New substance library to accelerate the search for active compounds

For the study, the enzyme endothiapepsin (grey) was combined with molecules from the fragment library. The analysis shows that numerous substances are able to dock to the enzyme (blue and orange molecules). Every substance found is a potential starting point for the development of larger molecules.

For the study, the enzyme endothiapepsin (grey) was combined with molecules from the fragment library. The analysis shows that numerous substances are able to dock to the enzyme (blue and orange molecules). Every substance found is a potential starting point for the development of larger molecules. © J. Wollenhaupt/HZB

The fragment libraries, which the MX team has assembled together with a group from the University of Marburg, are also available to users at BESSY II. The diagram shows the fragment-screening workflow.

The fragment libraries, which the MX team has assembled together with a group from the University of Marburg, are also available to users at BESSY II. The diagram shows the fragment-screening workflow. © HZB

In order to accelerate the systematic development of drugs, the MX team at the Helmholtz-Zentrum Berlin (HZB) and the Drug Design Group at the University of Marburg have established a new substance library. It consists of 1103 organic molecules that could be used as building blocks for new drugs. The MX team has now validated this library in collaboration with the FragMAX group at MAX IV. The substance library of the HZB is available for research worldwide and also plays a role in the search for substances active against SARS-CoV-2.

For drugs to be effective, they usually have to dock to proteins in the organism. Like a key in a lock, part of the drug molecule must fit into recesses or cavities of the target protein. For several years now, the team of the Macromolecular Crystallography Department (MX) at HZB headed by Dr. Manfred Weiss together with the Drug Design Group headed by Prof. Gerhard Klebe (University of Marburg) has therefore been working on building up what are known as fragment libraries. These consist of small organic molecules (fragments) with which the functionally important cavities on the surface of proteins can be probed and mapped. Protein crystals are saturated with the fragments and then analysed using powerful X-ray light. This allows three-dimensional structural information to be obtained at levels of atomic resolution. Among other things, it is possible to find out how well a specific molecule fragment docks to the target protein. The development of these substance libraries took place as part of the joint Frag4Lead research project and was funded by the German Federal Ministry of Education and Research (BMBF).

The MX team (MX stands for Macromolecular Crystallography) has now published the design of a chemically diverse fragment library called the “F2X-Universal“ library, which consists of 1,103 compounds. A representative selection of 96 compounds has been extracted from this library, which is referred to as the F2X Entry Screen. In the course of publishing the library, this selection has now been successfully tested and validated by the MX team of the HZB at the MAX IV X-ray source in Lund, Sweden and at BESSY II.

In the study, the HZB and MAX IV teams verified the efficiency of the F2X Entry library by screening endothiapepsin and the Aar2/RnaseH protein complex as the target enzymes. In the next step, the MX team will use the entire universal library.

“For the current study, the fragment screening experts at HZB - BESSY II worked very closely with the FragMAX project team at MAX IV“, said Dr. Uwe Müller from the MX team at HZB who helped to set up the three MX beamlines at BESSY II as well as the BioMAX beamline at MAX IV. “This enabled both partners to further develop their own technology platforms and use them for imaging the functional surfaces of different proteins. This will be an excellent basis for future collaboration between MAX IV and HZB.“

arö

  • Copy link

You might also be interested in

  • Green hydrogen: MXenes shows talent as catalyst for oxygen evolution
    Science Highlight
    09.09.2024
    Green hydrogen: MXenes shows talent as catalyst for oxygen evolution
    The MXene class of materials has many talents. An international team led by HZB chemist Michelle Browne has now demonstrated that MXenes, properly functionalised, are excellent catalysts for the oxygen evolution reaction in electrolytic water splitting. They are more stable and efficient than the best metal oxide catalysts currently available. The team is now extensively characterising these MXene catalysts for water splitting at the Berlin X-ray source BESSY II and Soleil Synchrotron in France.
  • SpinMagIC: 'EPR on a chip' ensures quality of olive oil and beer
    News
    04.09.2024
    SpinMagIC: 'EPR on a chip' ensures quality of olive oil and beer
    The first sign of spoilage in many food products is the formation of free radicals, which reduces the shelf-life and the overall quality of the food. Until now, the detection of these molecules has been very costly for the food companies. Researchers at HZB and the University of Stuttgart have developed a portable, small and inexpensive 'EPR on a chip' sensor that can detect free radicals even at very low concentrations. They are now working to set up a spin-off company, supported by the EXIST research transfer programme of the German Federal Ministry of Economics and Climate Protection. The EPRoC sensor will initially be used in the production of olive oil and beer to ensure the quality of these products.
  • Review on ocular particle therapy (OPT) by international experts
    Science Highlight
    03.09.2024
    Review on ocular particle therapy (OPT) by international experts
    A team of leading experts in medical physics, physics and radiotherapy, including HZB physicist Prof. Andrea Denker and Charité medical physicist Dr Jens Heufelder, has published a review article on ocular particle therapy. The article appeared in the Red Journal, one of the most prestigious journals in the field. It outlines the special features of this form of eye therapy, explains the state of the art and current research priorities, provides recommendations for the delivery of radiotherapy and gives an outlook on future developments.